Trials / Completed
CompletedNCT00532337
Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis
A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 285 (actual)
- Sponsor
- Ono Pharma USA Inc · Industry
- Sex
- Female
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-5334 | Placebo - 24/mos. |
| DRUG | ONO-5334 | 100mg QD /24 months |
| DRUG | ONO-5334 | 50mg BID /24 mos. |
| DRUG | ONO-5334 | 300mg QD /24 mos. |
| DRUG | ONO-5334 | Alendronate 70mg once weekly / 24 mos |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-07-01
- First posted
- 2007-09-20
- Last updated
- 2012-06-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00532337. Inclusion in this directory is not an endorsement.